Mandate

Vinge advises Anyfin in a capital procurement of approximately SEK 320 million

January 18, 2023 M&A

The new financing will be used in order to further strengthen Anyfin’s product portfolio on existing markets in Europe, to accelerate the development of new technology in order to help consumers to save money, and to improve the financial well-being of hundreds of thousands of Europeans.

Anyfin helps its customers to reduce their interest costs by refinancing original loans and providing better offers in respect of the customers’ loans.

Vinge’s team primarily consisted of Johan Larsson, Ellinor Wargenbrant and Nando Basic.

Read more>>>

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025